Twitter LinkedIn Français English REMUNERATION AND APPOINTMENT COMMITTEE Mr. Andréasson, Dr. Archinard and Mr Kress currently serve on our remuneration and appointments committee. Dr. Archinard is the chairperson of our remuneration and appointments committee. Sven Andreasson Currently, Sven Andreasson is administrator of Galenos. He is the former Chief Executive Officer of Isconova AB (Uppsala, Sweden), CEO of Beta-Cell NV (Brussels), Active Biotech AB (Lund, Sweden) and several companies in the Pharmacia group. He acquired extensive experience in the international biotechnology companies and in the pharmaceutical industry. Sven Andreasson received a BS degree in science and business administration and in Finance from Stockholm School of Economics and Business Administration. Philippe Archinard Philippe Archinard, Ph.D. has served as a member of our board of directors since 2013. Dr. Archinard is Deputy CEO, Innovation and Scientific Partnerships of the Institut Mérieux. He was General Manager, Chief Executive Officer and director of Transgene from 2004 to 2020, after spending 15 years in various senior positions with bioMérieux, including directing its U.S. subsidiary. Prior to joining Transgene, he served as chief executive officer of Innogenetics N.V., from 2000 to December 2004. Dr. Archinard is a chemical engineer, holds a Ph.D. in biochemistry from the University of Lyon (France), and completed Harvard Business School’s Program of Management PMD. Jean-Paul Kress Jean-Paul Kress is the Chief Executive Officer of Morphosys. He previously served as President and Chief Executive Officer of Syntimmune from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018. Prior to joining Syntimmune, Jean-Paul Kress served as Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Prior to this, Jean-Paul Kress worked at Sanofi Genzyme, Sanofi Pasteur MSD, Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe. He was a member of Sarepta Therapeutics’ Board of Directors from 2015 until 2017. Jean-Paul Kress holds an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in pharmacology and immunology from École Normale Supérieure in Paris. Investors Corporate Governance Board of Directors Audit Committee Remuneration and Appointment Committee Clinical Strategy Committee Stock Market Data SEC Filings AMF Regulated Information Shareholders Meeting Financial Calendar Analyst Coverage Webcasts Corporate Presentation Erytech PharmaSA 60 Avenue Rockefeller 69008 Lyon France Erytech Pharma Inc. 1 Main Street, Suite 300 Cambridge, MA 02142 USA About Us Technology Platform Pipeline Investors Newsroom Contact Opens in a new tab Opens in a new tab Terms & Conditions Copyright © 2021. Erytech Pharma. All rights reserved. By visiting this website, you are giving your consent for cookies to be used for us to improve your navigation experience.OKLEARN MORE Français English